title: Differential induction of peroxisomal enzymes by hypolipidaemics in human (HepG2) and rat (MH1C1) hepatoma cell lines.
abstract: Human (HepG2) and rat (MH1C1) hepatoblastoma cells were incubated with different concentrations of the hypolipidaemics cetaben, clofibrate and thyroxine. The enzymatic activities of catalase, peroxisomal bifunctional enzyme, succinate dehydrogenase, and 3-oxoacyl-CoA thiolase were measured. In order to determine the point of regulation of the enzymatic activities Northern and Slot blot experiments with probes for peroxisomal bifunctional enzyme, catalase and fatty acyl CoA oxidase were performed on total RNA. Catalase activity was enhanced in HepG2 cells treated with 3 mmol/l clofibric acid to 135% of control and the mRNA value to 2.6 fold, whereas in cetaben treated cells the enhancement (up to 119% of control) was less pronounced. In MH1C1 cells catalase activity was not changed by any of the drugs. The activity of the peroxisomal bifunctional enzyme was not affected in HepG2 cells by clofibric acid and cetaben, whereas the mRNA level was elevated to 2.3 fold by 10 micromol/l cetaben. At high concentrations of cetaben all enzyme activities were decreased in both cell lines due to its high cytotoxicity. Our data show that, due to the differences in the genomic organisation, the regulation of the enzyme activities is different in human and rat, but the results from the human and rat hepatoblastoma cells correlate with the findings in whole man and rat, so that a human in vitro system is more suitable for pharmacological tests. These results suggest that the human hepatoma cell line HepG2 may be a useful model system for studies of the influence of hypolipidaemics on the peroxisomal enzyme system.
authors.affiliation: Institut für Medizinische Chemie, Universität Wien, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Stangl
authors.forename: W
authors.initials: W
authors.lastname: Kovacs
authors.forename: P
authors.initials: P
authors.lastname: Böck
authors.forename: K
authors.initials: K
authors.lastname: Kremser
mesh_terms: D010129:4-Aminobenzoic Acid / Q000494:pharmacology; D000101:Acetyl-CoA C-Acetyltransferase / Q000096:biosynthesis*; D000818:Animals; D015152:Blotting, Northern; D006528:Carcinoma, Hepatocellular / Q000201:enzymology; D002374:Catalase / Q000096:biosynthesis*; D002460:Cell Line; D002470:Cell Survival; D015342:DNA Probes; D004790:Enzyme Induction; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000201:enzymology; D008114:Liver Neoplasms, Experimental / Q000201:enzymology; D008830:Microbodies / Q000201:enzymology* / Q000648:ultrastructure; D008854:Microscopy, Electron; D051381:Rats; D013385:Succinate Dehydrogenase / Q000096:biosynthesis*; D014407:Tumor Cells, Cultured; D062366:para-Aminobenzoates
chemical_list: D015342:DNA Probes; D000960:Hypolipidemic Agents; D062366:para-Aminobenzoates; C018246:cetaben; D002374:Catalase; D013385:Succinate Dehydrogenase; D000101:Acetyl-CoA C-Acetyltransferase; D010129:4-Aminobenzoic Acid